The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-β abundance

British Journal of Nutrition

Volumn 101, Issue 3, 2009, Pages 340-347

  Pallebage Gamarallage, Menuka M ^a,b   Galloway, Susan ^a,b   Johnsen, Russell ^c,d   Jian, Le ^a,b   Dhaliwal, Satvinder ^a,b   Mamo, John C L ^a,b  

^a CURTIN UNIVERSITY   (Australia)

^b Australian Technology Network   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d Australian Neuromuscular Research Institute   (Australia)

Author keywords

Amyloid beta; ; Cholesterol; Cholesterol modulating drugs; Chylomicrons

Indexed keywords

AMYLOID BETA PROTEIN; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; SATURATED FATTY ACID; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; LIPID ABSORPTION; LOW FAT DIET; MOUSE; NONHUMAN; POSTPRANDIAL STATE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; SMALL INTESTINE ABSORPTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; CHOLESTEROL INTAKE; DRUG EFFECT; FEMALE; INTESTINE ABSORPTION; METABOLISM; RANDOMIZATION;

MUS;

AMYLOID BETA-PROTEIN; ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, DIETARY; ENTEROCYTES; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INTESTINAL ABSORPTION; MICE; MICE, INBRED C57BL; PYRROLES; RANDOM ALLOCATION; TRIGLYCERIDES;

EID: 66849101796     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114508012269     Document Type: Article

References (48)

1. Selkoe DJ (1994) Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 10, 373-403.
2. Fukuoka A, Nakayama H & Doi K (2004) Immunohistochemical detection of β-amyloid and β-amyloid precursor protein in the canine brain and non-neuronal epithelial tissues. J Protein Folding Disord 1, 173-178.
3. Golde TE & Eckman CB (2001) Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discov Today 6, 1049-1055.
4. Haass C, Hung AY, Schlossmacher MG, Oltersdorf T, Teplow DB & Selkoe DJ (1993) β-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 268, 3021-3024.
5. Golde TE, Estus S, Younkin LH, Selkoe DJ & Younkin SG (1992) Processing of the amyloid protein-precursor to potentially amyloidogenic derivatives. Science 255, 728-730.
6. Haass C, Koo EH, Mellon A, Hung AY & Selkoe DJ (1992) Targeting of cell-surface β-amyloid precursor protein to lysosomes: Alternative processing into amyloid-bearing fragments. Nature 357, 500-503.
7. Greenfield JP, Tsai J, Gouras GK, Hai B, Thinakaran G, Checler F, Sisodia SS, Greengard P & Xu H (1999) Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer β-amyloid peptides. Neurobiol 96, 742-747.
8. Turner RS, Suzuki N, Chyung ASC, Younkin SG & Lee WMY (1996) Amyloids β40 and β42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem 271 8966-8970.
9. Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y & Haass C (1997) Intracellular generation and accumulation of amyloid β-peptide terminating at amino acid 42. J Biol Chem 272, 16085-16088.
10. Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM & Zlokovic BV (2005) IgG-assisted age-dependent clearance of Alzheimer's amyloid β-peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 25, 11495-11503.
11. Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B & Zlokovic BV (2002) Circulating amyloid β-peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol 38, 308-313.
12. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP & Gajdusek DC (1989) Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A 86, 7696-7710.
13. Chen M, Inestrosa NC, Ross GS & Fernandez HL (1995) Platelets are the primary source of amyloid β-peptide in human blood. Biochem Biophys Res Commun 213, 96-103.
14. Galloway S, Jian L, Johnsen R, Chew S & Mamo JCL (2007) β-Amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. J Nutr Biochem 18, 279-284.
15. George AJ, Holsinger RMD, McLean CA, Laughton KM, Beyreuther K, Evin G, Matsters CL & Li Q (2004) APP intracellular domain is increased and soluble Aβ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease. Neurobiol Dis 16 124-132.
16. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K & Papolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
17. Shie F, Jin L, Cook DG, Leverenz JB & LeBoeuf RC (2002) Diet-induced hypercholesterolemia enhances brain Aβ accumulation in transgenic mice. Neuroreport 13, 455-459.
18. Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T & Gross DR (1994) Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126, 88-94.
19. Giri R, Selvaraj S, Miller CA, Hofman F, Yan SD, Stern D, Zlokovic BV & Kalra VK (2002) Effect of endothelial cell polarity on β-amyloid-induced migration of monocytes across normal and AD endothelium. Am J Physiol Cell Physiol 283, C895-C904.
20. LaRue R, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, Deane R & Zlokovic BV (2004) Method for measurement of the blood-brain barrier permeability in the perfused mouse brain. J Neurosci Methods 138, 233-242.
21. Sparks DL (1996) Intraneuronal β-amyloid immunoreactivity in the CNS. Neurobiol Aging 17, 291-299.
22. 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98, 5856-5861.
23. Wolozin B (2004) Cholesterol, statins and dementia. Curr Opin Lipidol 15, 667-672.
24. Shen H, Howles P & Tso P (2001) From interaction of lipidic vehicles with intestinal epithelial cell membranes to the formation and secretion of chylomicrons. Advanced Drug Del Rev 50, S102-S125.
25. Simons K & Ikonen E (2000) How cells handle cholesterol. Science 290, 1721-1726.
26. Mahmood-Hussain M (2000) A proposed model for the assembly of chylomicrons. Atherosclerosis 148, 1-15.
27. Cesar TB, Oliveira MRM, Mesquita CH & Maranhao RC (2006) High cholesterol intake modifies chylomicron metabolism in normolipidemic young men. J Nutr 136, 971-976.
28. 2 cells. Atherosclerosis 161, 55-63.
29. James AP & Mamo JCL (2005) The immunodetection of lipoprotein-bound amyloid-β is attenuated because of the presence of lipids. Ann Clin Biochem 42, 70-72.
30. James AP, Pal S, Gennat HC, Vine DF & Mamo JCL (2003) The incorporation and metabolism of amyloid-β into chylomicron-like lipid emulsions. J Alz Dis 5, 179-188.
31. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I & von Bergmann K (2002) Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106 1943-1948.
32. Davis HR Jr, Zhu L, Hoos LM, et al. (2004) Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 279, 33586-33592.
33. Naoumova RP, Dum S, Rallidis L, Abu-Muhana O, Neuwirth C, Rendell NB, Taylor GW & Thompson GR (1997) Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. J Lipid Res 38 1496-1500.
34. Mikaelian I, Nanney LB, Parman KS, et al. (2004) Antibodies that label paraffin-embedded mouse tissues: A collaborative endeavor. Toxic Path 32, 181-191.
35. Howland DS, Trusko SP, Savage MJ, et al. (1998) Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol. J Biol Chem 273, 16576-16582.
36. Altmann SW, Davis HR, Zhu L, et al. (2004) Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303, 1201-1204.
37. Park I, Hwang EM, Honga HS, Boo JH, Oh SS, Lee J, Jung MW, Bang OY, Kim SU & Mook-Jung I (2003) Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 24, 637-643.
38. Frears ER, Stephens DJ, Walters CE, Davies H & Austen BM (1999) The role of cholesterol in the biosynthesis of β-amyloid. Neuroreport 10, 1699-1705.
39. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, Strooper BD & Dotti CG (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Clin Biochem 167, 953-960.
40. Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R & Hartmann T (2002) Inhibition of intracellular cholesterol transport alters presenilin localisation and amyloid precursor protein processing in neuronal cells. J Neurosci 22, 1679-1689.
41. Puglielli L, Konopka G, Pack-Chung E, Ingano LAM, Berezovska O, Hyman BT, Chang TY, Tanzi RE & Kovacs DM (2001) Acyl-coenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid β-peptide. Nature Cell Biol 3, 905-912.
42. Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, Duff K, Pappolla M & Refolo LM (2002) Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 19, 155-161.
43. Reiss AB & Wirkowski E (2007) Role of HMG CoA reductase inhibitors in neurological disorders: Progress to date. Drugs 67, 2111-2120.
44. Sabbagh M, Zahiri HR, Ceimo J, Cooper K, Gaul W, Connor D & Sparks DL (2004) Is there a characteristic lipid profile in Alzheimer's disease? J Alzheimers Dis 6, 585-589.
45. Laitinen MH, Ngandu T, Rovio S, Helkala EL, Uusitalo U, Viitanen M, Nissinen A, Tuomilehto J, Soininen H & Kivipelto M (2006) Fat intake at midlife and risk of dementia and Alzheimer's disease: A population-based study. Dement Geriatr Cogn Disord 22, 99-107.
46. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW & Wolf PA (2006) Plasma phosphatidylcholine docosahexanoic acid content and risk of dementia and Alzhimer disease: the Framingham Heart Study. Arch Neurol 63, 1545-1550.
47. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T & Tanila H (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on β-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23, 563-572.
48. Liu Y, Yang L, Conde-Knape K, Beher D, Shearman MS & Shacter NS (2004) Fatty acids increase presenilin-1 levels and γ-secretase activity in PSwt-1 cells. J Lipid Res 45, 2368-2376.